Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
95% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. TKMR: No Debt )
TKMR' s 10-Year Cash to Debt Range
Min: 14.07   Max: No Debt
Current: No Debt

Equity to Asset 0.83
TKMR's Equity to Asset is ranked higher than
86% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TKMR: 0.83 )
TKMR' s 10-Year Equity to Asset Range
Min: -1   Max: 0.93
Current: 0.83

-1
0.93
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
84% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 11.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -78.59
TKMR's Operating margin (%) is ranked higher than
69% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. TKMR: -78.59 )
TKMR' s 10-Year Operating margin (%) Range
Min: -22383.33   Max: 16.57
Current: -78.59

-22383.33
16.57
Net-margin (%) -90.95
TKMR's Net-margin (%) is ranked higher than
68% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. TKMR: -90.95 )
TKMR' s 10-Year Net-margin (%) Range
Min: -19172.92   Max: 209.94
Current: -90.95

-19172.92
209.94
ROE (%) -23.76
TKMR's ROE (%) is ranked higher than
69% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. TKMR: -23.76 )
TKMR' s 10-Year ROE (%) Range
Min: -203.37   Max: 11590.38
Current: -23.76

-203.37
11590.38
ROA (%) -19.61
TKMR's ROA (%) is ranked higher than
71% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. TKMR: -19.61 )
TKMR' s 10-Year ROA (%) Range
Min: -71.02   Max: 299.6
Current: -19.61

-71.02
299.6
ROC (Joel Greenblatt) (%) -885.14
TKMR's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. TKMR: -885.14 )
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -957.47   Max: 171.36
Current: -885.14

-957.47
171.36
Revenue Growth (%) -21.30
TKMR's Revenue Growth (%) is ranked higher than
64% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. TKMR: -21.30 )
TKMR' s 10-Year Revenue Growth (%) Range
Min: -27.8   Max: 236.2
Current: -21.3

-27.8
236.2
EBITDA Growth (%) -12.30
TKMR's EBITDA Growth (%) is ranked higher than
72% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. TKMR: -12.30 )
TKMR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 38
Current: -12.3

0
38
EPS Growth (%) -8.50
TKMR's EPS Growth (%) is ranked higher than
77% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. TKMR: -8.50 )
TKMR' s 10-Year EPS Growth (%) Range
Min: -47.1   Max: 32
Current: -8.5

-47.1
32
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TKMR Guru Trades in

TKMR Guru Trades in

Q1 2013

TKMR Guru Trades in Q1 2013

Jean-Marie Eveillard 25,000 sh (New)
» More
Q2 2013

TKMR Guru Trades in Q2 2013

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05 $ 13.05175%0
Jean-Marie Eveillard 2013-03-31 New Buy$4.35 - $5.44 $ 13.05176%25000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.20
TKMR's P/B is ranked higher than
64% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. TKMR: 4.20 )
TKMR' s 10-Year P/B Range
Min: 0.32   Max: 261
Current: 4.2

0.32
261
P/S 13.59
TKMR's P/S is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. TKMR: 13.59 )
TKMR' s 10-Year P/S Range
Min: 0.72   Max: 29.61
Current: 13.59

0.72
29.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.42
TKMR's Price/Net Cash is ranked higher than
81% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. TKMR: 4.42 )
TKMR' s 10-Year Price/Net Cash Range
Min: 0.66   Max: 37.5
Current: 4.42

0.66
37.5
Price/Net Current Asset Value 4.40
TKMR's Price/Net Current Asset Value is ranked higher than
82% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. TKMR: 4.40 )
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.64   Max: 13.64
Current: 4.4

0.64
13.64
Price/Tangible Book 4.19
TKMR's Price/Tangible Book is ranked higher than
70% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. TKMR: 4.19 )
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 4.52
Current: 4.19

0.59
4.52
Price/DCF (Projected) 7.58
TKMR's Price/DCF (Projected) is ranked lower than
64% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. TKMR: 7.58 )
TKMR' s 10-Year Price/DCF (Projected) Range
Min: 4.63   Max: 5.01
Current: 7.58

4.63
5.01
Price/Median PS Value 4.44
TKMR's Price/Median PS Value is ranked lower than
74% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. TKMR: 4.44 )
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 2.71
Current: 4.44

0.32
2.71
Forward Rate of Return (Yacktman) -7.21
TKMR's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. TKMR: -7.21 )
TKMR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 82.7   Max: 708.9
Current: -7.21

82.7
708.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany
Tekmira Pharmaceuticals Corporation develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. It also develops TKM-ApoB that has completed Phase I clinical trials to reduce the production of apolipoprotein B 100 in patients with high levels of low-density lipoprotein cholesterol. In addition, the company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for NAS:TKMR

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
How Did You File and Do You Owe? - Real Time Insight Apr 14 2014 - ZACKS

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide